Four classes of agents that can be used to treat multiple myeloma.

Slides:

Advertisements

Similar presentations

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Gliomas slide presentation is not an independent educational.

Advertisements

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Lung Cancer Tumour Markers

Advances in Molecular Biology of Lung Disease

A: inhibition of the erbB2 receptor abolished the protective effects of NRG1 on cTnI and cTnT in NRVM. NRVM were treated with Dox-NRG1 (20 ng/ml) in the.

Relapsed/Refractory Multiple Myeloma: Defining Refractory Disease and Identifying Strategies to Overcome Resistance David S. Siegel Seminars in Hematology

by Rogelio Zamilpa, and Merry L. Lindsey

Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

MAPK pathway inhibitors.

BRAF inhibitor: targeted therapy in hairy cell leukemia

Potential pathways directly linking obesity with cancer.

Christian Posch, Brian D

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Small-molecule inhibitor QLT-0267 suppresses ILK activity and inhibits its downstream signaling. Small-molecule inhibitor QLT-0267 suppresses ILK activity.

Figure 4 Possible combination therapies CDK4/6 inhibitors

Figure 3 Defects in the T cell receptor signalling pathway

Kinase inhibitors: Vice becomes virtue

Personalizing Therapy for Colorectal Cancer

Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung.

Nat. Rev. Urol. doi: /nrurol

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

Personalizing Therapy for Colorectal Cancer

Rapamycin in transplantation: A review of the evidence

The Increasing Diversity of KRAS Signaling in Pancreatic Cancer

Schematic representation of main EGFR-TKIs resistance mechanisms.

Targeted Therapies in Melanoma: Translational Research at Its Finest

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

Andrzej T. Slominski, MD, PhD Mayo Clinic Proceedings

Schematic view of Trk receptors signalling, showing the three major pathways involved in cell differentiation and survival. Schematic view of Trk receptors.

Mechanical stretch induces podocyte hypertrophy in vitro1

Identification of TOR Signaling Complexes

Autoradiographs of cDNA gene array of regulatory genes from untreated control (column A) and quercetin-treated (column B) cells. Autoradiographs of cDNA.

Melanoma: New Insights and New Therapies

Nat. Rev. Urol. doi: /nrurol

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Autophagy in kidney disease and aging: lessons from rodent models

Do the Side Effects of BRAF Inhibitors Mimic RASopathies?

The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing Marieke Hylebos, MSc, Guy Van Camp, PhD, Jan P van.

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET- Mutated Tumor Marc-Antoine Benderra, MD, Sandrine Aspeslagh, PhD, Sophie.

Nephrology Crosswords: Hemodialysis

Volume 139, Issue 2, Pages e3 (August 2010)

Localization of selected clones in mammalian COS-7 cells.

Low oxygen stimulates the immune system

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Figure 4. p38α mitogen-activated protein kinase (MAPK) blockade reduces interstitial volume in obstructed kidneys but does not reduce the number of infiltrating.

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

Platelet-derived growth factor (PDGF) signalling pathway.

Volume 69, Issue 11, Pages (June 2006)

Jinhua Tang, Na Liu, Shougang Zhuang Kidney International

The RAS-MEK-ERK pathway represents a chain of protein signalling pathway that responds to a mitogen binding to a cell surface receptor. The RAS-MEK-ERK.

Tobias B. Huber, Gerd Walz, E Wolfgang Kuehn Kidney International

Schematic representation of signaling by EBV EBNA-2.

Ca2+ infusion rates during all three protocol versions.

The rudimentary human β-cell mitogenic signaling road map.

Class 1 phosphatidylinositol 3-kinase (PI3K) p85 subunit dominant negative adenovirus regulates Pax2 and GAPDH abundance in NRK-52E cells. Class 1 phosphatidylinositol.

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

A loading dose decreases the time to achieve the target concentration.

B7-H1–induced reverse signals in myeloma cells.

We identified 200 Android and 178 iOS apps using 4 search terms and narrowed this to 12 Android apps, 11 iOS apps, and 5 dual-platform apps after applying.

Cisplatin (Cis) nephrotoxicity is, in part, related to its uptake by proximal tubular cells. Cisplatin (Cis) nephrotoxicity is, in part, related to its.

Distribution of percent consistent facility aspirin use.

Curcumin suppresses the expression of antiapoptotic proteins in multiple myeloma cells. Curcumin suppresses the expression of antiapoptotic proteins in.

New dialysis starts in the United States by year in patients with and without diagnosis of diabetes. New dialysis starts in the United States by year in.

As the patient nears the end of life (dashed arrow), there is an increasing focus on symptom control and patient goals of care and a shift in the approach.

BCR/ABL expression, tyrosine phosphorylation, and signaling in dasatinib- and imatinib-resistant cell lines and the ubiquitin inhibitor lactacystin modifies.

Model of immunosuppressive drug action in lymphocyte activation.

Schematic representation of signaling pathways associated with cannabinoid receptor activation induced by its agonists. Schematic representation of signaling.

Study protocol. Study protocol. All participants were studied on four occasions: Twice before and twice after an 8-wk treatment period on low-dosage, low.

Presentation transcript:

Four classes of agents that can be used to treat multiple myeloma. Four classes of agents that can be used to treat multiple myeloma. Akt, serine-threonine protein kinase B; BRAF, v-Raf murine sarcoma viral oncogene homolog B; HDAC, histone deactylase; MEK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; PD, programmed cell death protein; SLAMF7, signaling lymphocytic activation molecule F7. Rimda Wanchoo et al. CJASN 2017;12:176-189 ©2017 by American Society of Nephrology